{"protocolSection":{"identificationModule":{"nctId":"NCT00546819","orgStudyIdInfo":{"id":"V211-017"},"secondaryIdInfos":[{"id":"2006_557"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)","officialTitle":"A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids"},"statusModule":{"statusVerifiedDate":"2017-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-10"},"primaryCompletionDateStruct":{"date":"2010-08","type":"ACTUAL"},"completionDateStruct":{"date":"2010-08","type":"ACTUAL"},"studyFirstSubmitDate":"2007-10-17","studyFirstSubmitQcDate":"2007-10-17","studyFirstPostDateStruct":{"date":"2007-10-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-07-20","resultsFirstSubmitQcDate":"2011-07-20","resultsFirstPostDateStruct":{"date":"2011-08-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-03-14","lastUpdatePostDateStruct":{"date":"2017-04-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The purpose of the study was to assess the safety, tolerability, and immunogenicity of ZOSTAVAX™ in patients receiving chronic/maintenance corticosteroids."},"conditionsModule":{"conditions":["Herpes Zoster"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":309,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"ZOSTAVAX™","type":"EXPERIMENTAL","description":"Participants administered ZOSTAVAX™ on Day 1.","interventionNames":["Biological: Zoster Vaccine, Live"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants administered Placebo on Day 1.","interventionNames":["Biological: Comparator: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Zoster Vaccine, Live","description":"A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1","armGroupLabels":["ZOSTAVAX™"],"otherNames":["V211"]},{"type":"BIOLOGICAL","name":"Comparator: Placebo","description":"A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Serious Adverse Events (SAE)","description":"A serious adverse event is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \"other important medical event\" based on medical judgement.","timeFrame":"Up to 182 days postvaccination"}],"secondaryOutcomes":[{"measure":"Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibodies at 42 Days Postvaccination","description":"The Geometric Mean Titer (GMT) of VZV antibodies in participants' serum samples was assessed by a glycoprotein enzyme-linked immunosorbent assay (gpELISA).","timeFrame":"42 days postvaccination"},{"measure":"Geometric Mean Fold Rise (GMFR) of the VZV Antibody Response From Day 1 to Day 42 Postvaccination.","description":"The geometric mean fold rise (GMFR) of the VZV antibodies from Day 1 to Week 6 postvaccination.","timeFrame":"42 days postvaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Varicella-history positive, herpes zoster (HZ)-history negative patients\n* 60 years of age and older receiving chronic/maintenance systemic corticosteroid therapy at a daily dose of 5 to 20 mg of prednisone or equivalent for at least the 2 weeks immediately prior to enrollment and expected to continue to receive a daily dose of 5 to 20 mg of prednisone or equivalent for the 6-week primary safety follow-up period (dose may vary within this range during the 6-week postvaccination period)\n* All females enrolling must be postmenopausal\n\nExclusion Criteria:\n\n* Patients with a history of hypersensitivity reaction to gelatin or neomycin\n* Prior receipt of varicella or zoster vaccine; prior history of herpes zoster\n* Immune globulin and/or blood products given within 5 months prior to or expected within the 6-week postvaccination period\n* Receipt of any live virus vaccinations within 1 month or receipt of any inactivated vaccinations within 7 days prior to enrollment\n* Known immune deficiency that is caused by a medical condition\n* Any use in the 8 weeks prior to vaccination or for 6 weeks after vaccination other medications which may suppress the immune system including methotrexate, corticosteroids at a daily dose greater than 20 mg of prednisone or equivalent, agents used to treat cancer, or medications which alter the level of the immune response used to treat arthritis or other illnesses\n* Concomitant use of antiviral therapy\n* A history of alcohol abuse or recreational drug use","healthyVolunteers":false,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"25964168","type":"RESULT","citation":"Russell AF, Parrino J, Fisher CL Jr, Spieler W, Stek JE, Coll KE, Su SC, Xu J, Li X, Schlienger K, Silber JL. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. Vaccine. 2015 Jun 17;33(27):3129-34. doi: 10.1016/j.vaccine.2015.04.090. Epub 2015 May 8."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final\\_Updated%20July\\_9\\_2014.pdf\n\nhttp://engagezone.msd.com/ds\\_documentation.php"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"ZOSTAVAX™","description":"Participants administered ZOSTAVAX™ on Day 1."},{"id":"FG001","title":"Placebo","description":"Participants administered Placebo on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"207"},{"groupId":"FG001","numSubjects":"102"}]},{"type":"VACCINATED","achievements":[{"groupId":"FG000","numSubjects":"206"},{"groupId":"FG001","numSubjects":"100"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"199"},{"groupId":"FG001","numSubjects":"96"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"6"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"ZOSTAVAX™","description":"Participants administered ZOSTAVAX™ on Day 1."},{"id":"BG001","title":"Placebo","description":"Participants administered Placebo on Day 1."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"207"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"309"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69.8","spread":"6.9"},{"groupId":"BG001","value":"69.9","spread":"7.2"},{"groupId":"BG002","value":"69.8","spread":"7.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"140"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"220"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"89"}]}]}]},{"title":"Daily Corticosteroid Dose Stratum","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"5 to 10 mg of prednisone or equivalent","categories":[{"measurements":[{"groupId":"BG000","value":"182"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"270"}]}]},{"title":">10 to 20 mg of prednisone or equivalent","categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"39"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAE)","description":"A serious adverse event is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \"other important medical event\" based on medical judgement.","populationDescription":"All participants who were vaccinated and had any safety\n\nfollow-up were included in the safety analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to 182 days postvaccination","groups":[{"id":"OG000","title":"ZOSTAVAX™","description":"Participants administered ZOSTAVAX™ on Day 1."},{"id":"OG001","title":"Placebo","description":"Participants administered Placebo on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"99"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"11"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibodies at 42 Days Postvaccination","description":"The Geometric Mean Titer (GMT) of VZV antibodies in participants' serum samples was assessed by a glycoprotein enzyme-linked immunosorbent assay (gpELISA).","populationDescription":"Per-protocol population: All vaccinated participants who had serology results and who had no protocol deviations that would interfere with the evaluation of VZV-specific gpELISA antibody response.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"gpELISA units/mL","timeFrame":"42 days postvaccination","groups":[{"id":"OG000","title":"ZOSTAVAX™","description":"Participants administered ZOSTAVAX™ on Day 1."},{"id":"OG001","title":"Placebo","description":"Participants administered Placebo on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"531.1","lowerLimit":"453.3","upperLimit":"622.1"},{"groupId":"OG001","value":"224.3","lowerLimit":"169.8","upperLimit":"296.2"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) of the VZV Antibody Response From Day 1 to Day 42 Postvaccination.","description":"The geometric mean fold rise (GMFR) of the VZV antibodies from Day 1 to Week 6 postvaccination.","populationDescription":"Per-protocol population: All vaccinated participants who had serology results and who had no protocol deviations that would interfere with the evaluation of VZV-specific gpELISA antibody response.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"42 days postvaccination","groups":[{"id":"OG000","title":"ZOSTAVAX™","description":"Participants administered ZOSTAVAX™ on Day 1."},{"id":"OG001","title":"Placebo","description":"Participants administered Placebo on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"2.0","upperLimit":"2.7"},{"groupId":"OG001","value":"1.1","lowerLimit":"1.0","upperLimit":"1.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 182 days postvaccination for serious adverse events and 42 days postvaccination for other adverse events.","eventGroups":[{"id":"EG000","title":"ZOSTAVAX™","description":"Participants administered ZOSTAVAX™ on Day 1.","seriousNumAffected":21,"seriousNumAtRisk":204,"otherNumAffected":43,"otherNumAtRisk":204},{"id":"EG001","title":"Placebo","description":"Participants administered Placebo on Day 1.","seriousNumAffected":11,"seriousNumAtRisk":99,"otherNumAffected":10,"otherNumAtRisk":99}],"seriousEvents":[{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Hypertensive heart disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Goitre","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Food poisoning","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Inguinal hernia, obstructive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Cellulitis of male external genital organ","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Gastritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Herpes zoster ophthalmic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Kidney infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":204},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":99}]},{"term":"Scrotal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Comminuted fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Complex regional pain syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Bipolar disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":204},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":99}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":204},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":99}]}],"otherEvents":[{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":36,"numAtRisk":204},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":99}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":22,"numAtRisk":204},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":99}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":23,"numAtRisk":204},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":99}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. SPONSOR review can be expedited to meet publication guidelines."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp","email":"ClinicalTrialsDisclosure@merck.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Belgium","France","Germany","Puerto Rico","United Kingdom","United States"]},"conditionBrowseModule":{"meshes":[{"id":"D006562","term":"Herpes Zoster"}],"ancestors":[{"id":"D000073618","term":"Varicella Zoster Virus Infection"},{"id":"D006566","term":"Herpesviridae Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"D053061","term":"Herpes Zoster Vaccine"}],"ancestors":[{"id":"D019433","term":"Chickenpox Vaccine"},{"id":"D022283","term":"Herpesvirus Vaccines"},{"id":"D014765","term":"Viral Vaccines"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"}]}},"hasResults":true}